STA Pharmaceutical, a WuXi AppTec Company

stapharma.com

STA Pharmaceutical
WuXi STA, a WuXi AppTec company, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with four sites in China and two sites in the United States and one in Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

VIVERA PARTNERS WITH NINDS OF NIH TO IDENTIFY POTENTIAL STUTTERING TREATMENTS

Vivera Pharmaceuticals, Inc. | May 18, 2022

news image

Vivera Biosciences, a division of Vivera Pharmaceuticals dedicated to the research and development of innovative medical technologies and pharmaceutical therapies, is pleased to announce its collaborative progress on a Cooperative Research and Development Agreement with the National Institute of Neurological Disorders and Stroke an Institute within the National Institutes of Health that aims to foster and advance cutting-edge neuroscience research to reduce the burden of neurological disease. Th...

Read More

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

news image

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

news image

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

Business Insights, PHARMACY MARKET

FRAMEWORK SOLUTIONS ANNOUNCES ACQUISITION OF ONIX LIFE SCIENCES

Framework Solutions, LLC | March 02, 2023

news image

On March 1, 2023, Framework Solutions, a leading clinical to commercial solutions provider, announced that it has acquired ONIX Life Sciences, a consultancy focused on regulatory operations services for the life sciences industry. The acquisition will enable both firms to expand their global reach and strengthen their service capabilities by providing clients with a broader range of critical services. ONIX's expertise in eCTD Submissions, Publishing, and eCTD Lifecycle Management has h...

Read More
news image

Pharmacy Market

VIVERA PARTNERS WITH NINDS OF NIH TO IDENTIFY POTENTIAL STUTTERING TREATMENTS

Vivera Pharmaceuticals, Inc. | May 18, 2022

Vivera Biosciences, a division of Vivera Pharmaceuticals dedicated to the research and development of innovative medical technologies and pharmaceutical therapies, is pleased to announce its collaborative progress on a Cooperative Research and Development Agreement with the National Institute of Neurological Disorders and Stroke an Institute within the National Institutes of Health that aims to foster and advance cutting-edge neuroscience research to reduce the burden of neurological disease. Th...

Read More
news image

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More
news image

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More
news image

Business Insights, PHARMACY MARKET

FRAMEWORK SOLUTIONS ANNOUNCES ACQUISITION OF ONIX LIFE SCIENCES

Framework Solutions, LLC | March 02, 2023

On March 1, 2023, Framework Solutions, a leading clinical to commercial solutions provider, announced that it has acquired ONIX Life Sciences, a consultancy focused on regulatory operations services for the life sciences industry. The acquisition will enable both firms to expand their global reach and strengthen their service capabilities by providing clients with a broader range of critical services. ONIX's expertise in eCTD Submissions, Publishing, and eCTD Lifecycle Management has h...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us